IGFBP3 mRNA Expression in Benign and Malignant Breast Tumors

Article

Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells.

Background
Most previous studies have focused on evaluating the association between circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and breast cancer risk. Emerging evidence over the past few years suggests that IGFBP-3 may act directly on mammary epithelial cells.

Methods
To understand the role of IGFBP-3 in breast tumorigenesis, we investigated IGFBP3 mRNA expression levels in benign and malignant breast tumors and their adjacent normal tissues using real-time quantitative PCR.

Results
Cancer tissues had significantly lower IGFBP3 expression than benign tumor tissues (p < 0.001). IGFBP3 expressions in both tumor and adjacent tissues were higher in patients who had proliferative benign tumors than those who had non-proliferative benign tumors. Among patients with benign breast disease, IGFBP3 expression in the tumor was significantly higher than that in their adjacent normal tissue. There were no apparent associations of IGFBP3 expression in cancer tissues with either overall survival or disease-free survival in a cohort of 521 breast cancer patients.

Conclusions
Our findings suggest that the expression level of IGFBP3 in breast tissues may be involved in breast tumorigenesis.

References:

Breast Cancer Research 2007, 9:R2 doi:10.1186/bcr1634

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Recent Videos
USPSTF releases new recommendations for breast cancer screening | Image Credit: uclahealth.org
Related Content
© 2024 MJH Life Sciences

All rights reserved.